GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » Net-Net Working Capital

Sequenom (Sequenom) Net-Net Working Capital : $-0.70 (As of Jun. 2016)


View and export this data going back to 2000. Start your Free Trial

What is Sequenom Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Sequenom's Net-Net Working Capital for the quarter that ended in Jun. 2016 was $-0.70.

The industry rank for Sequenom's Net-Net Working Capital or its related term are showing as below:

SQNM's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.265
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Sequenom Net-Net Working Capital Historical Data

The historical data trend for Sequenom's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom Net-Net Working Capital Chart

Sequenom Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 -0.12 -0.97 -0.75 -0.63

Sequenom Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.58 -0.63 -0.69 -0.70

Competitive Comparison of Sequenom's Net-Net Working Capital

For the Biotechnology subindustry, Sequenom's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequenom's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Sequenom's Price-to-Net-Net-Working-Capital falls into.



Sequenom Net-Net Working Capital Calculation

Sequenom's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2015 is calculated as

Net-Net Working Capital(A: Dec. 2015 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(76.17+0.75 * 6.421+0.5 * 2.417-157.18
-0-0)/118.568
=-0.63

Sequenom's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2016 is calculated as

Net-Net Working Capital(Q: Jun. 2016 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(61.328+0.75 * 7.284+0.5 * 4.276-151.812
-0-0)/119.243
=-0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Sequenom  (NAS:SQNM) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Sequenom Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Sequenom's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequenom (Sequenom) Business Description

Traded in Other Exchanges
N/A
Address
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
Executives
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler director
Charles P Slacik director 250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton officer: Sr VP, GC & Secretary 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver officer: SVP & CFO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas director
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii director, officer: Chairman, President & Sec 22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg director, officer: EVP and Treasurer P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis director REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch officer: President & CEO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Sequenom (Sequenom) Headlines

From GuruFocus

Context Capital Management's Top Buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-15-2015

Sequenom Officer Acquires 30,000 Shares

By Jennifer Chiou Jennifer Chiou 05-10-2016

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010

Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares

By GuruFocus GuruFocus 08-03-2012

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010